Fast track your drug development programs with Syngene
Preclinical to commercial
Syngene International, a global integrated research, development, and manufacturing services company, will be exhibiting at CPHI Worldwide 2024, Milan, Booth #7C114, from October 8-10.
With more than three decades of experience, 400+ active global clients, and 400+ patents held with clients, Syngene offers end-to-end services from preclinical to commercial across modalities.
What makes Syngene the preferred CRO-CDMO partner
India advantage
Headquartered in India, we offer the benefits of cost-efficiency and supply stability. We have a network of 2500+ suppliers spread across 30+ countries, flexible manufacturing capacity, and world-class scientists to support your R&D programs.
End-to-end services
Our scientific solutions are across therapeutic areas and modalities, including small molecules, biologics, oligonucleotides, and peptides.
Manufacturing capacity
We offer flexible manufacturing capacity, including custom manufacturing from our USFDA, and EMA-approved facilities – 70,000L for small molecules and 28,000L (expandible to 48,000L) for biologics. We also have a high-speed fill-finish facility with a capacity of 1 million vials/day.
Biologics expertise
Our ongoing expansion in capabilities and capacity in Biologics has established Syngene as one of the largest CRDMOs in India. As a trusted partner, we have delivered 100 commercial batches in the last two years. Our track record of over 250 GMP batches, 150+ projects, and support for over 25 INDs across biologics modalities demonstrates our expertise.
Sustainability
Our continuous commitment to excellence in environmental, social, and governance (ESG) practices has resulted in the company securing a silver rating in the prestigious EcoVadis sustainability index for FY2024, placing us among the top 15% of companies assessed worldwide.
Contact us
To book a meeting with our experts, visit: www.syngeneintl.com/contact-us
